Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart ultrasound may reveal who gets the most from heart failure drug

NCT ID NCT07088471

Knowledge-focused Sponsor: Connolly Hospital Blanchardstown Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at 334 adults with heart failure and reduced pumping ability. Researchers used ultrasound to measure left atrial strain before and after starting sacubitril/valsartan, a drug known to improve survival. The goal was to see if these measurements could predict who responds best to the drug, potentially helping doctors tailor treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Sacubitril/valsartan (a combination drug that helps the heart work better)
What this could lead to
If successful, this could help doctors predict which heart failure patients will benefit most from sacubitril/valsartan, leading to more personalized treatment.
What could go wrong
This is a completed observational analysis, not a new treatment trial. The findings may not change practice directly and need further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

334 people

The number who actually took part.

Started

Nov 2024

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Heart Failure with reduced ejection fraction (HFrEF) patients on stable guideline-directed medical therapy prior to commencing sacubitril/valsartan (SV) will be retrospectively identified

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults diagnosed with heart Failure with reduced ejection fraction (HFrEF), i.e. LVEF ≤40% by Simpson's method on transthoracic echocardiography 2. Stable guideline-directed medical therapy prior to sacubitril/valsartan (SV) initiation 3. New York Heart Association classes II-III symptom status 4. Guideline-directed up-titration of SV therapy to the maximum tolerated dose 5. Transthoracic echocardiogram and NT-proBNP prior to SV initiation and at 3 months post commencement of therapy Exclusion Criteria: 1. Patients not in sinus rhythm at time of echocardiograms (precludes left atrial strain analysis) 2. Sub-optimal echocardiographic images to allow measurement of left atrial strain 3. Prior mitral valve intervention (left atrial strain assessment unreliable in this cohort) 4. Severe mitral regurgitation (left atrial strain assessment unreliable in this cohort)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure and reduced ejection fraction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure and reduced ejection fraction

Contacts and locations

Locations

  • Connoly Hospital Blanchardstown

    Dublin, Ireland

More trials for these conditions

Other studies related to the condition(s) this trial covers.